<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>BioWorld Science</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Pharma industry faces long haul to get return on investment from AI</title>
      <description>
        <![CDATA[Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on investment (ROI). “I would say a lot of companies sort of get this big excitement about AI, but then when you look at how much ROI they get, it’s actually very little. And that’s because the workflow and the process, end-to-end, isn’t mapped to really understand where AI can truly make an impact,” said Laura Matz, chief science and technology officer at Merck KGaA.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730716</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730716-pharma-industry-faces-long-haul-to-get-return-on-investment-from-ai</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-drug-development-illustration.webp?t=1776978683" type="image/jpeg" medium="image" fileSize="1049020">
        <media:title type="plain">Glowing neural network inside a transparent capsule surrounded by a large language model</media:title>
      </media:content>
    </item>
    <item>
      <title>Jiangsu Carephar Pharmaceutical describes new AT2 receptor agonists</title>
      <description>
        <![CDATA[Jiangsu Carephar Pharmaceutical Co. Ltd. has patented angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of idiopathic pulmonary fibrosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730665</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730665-jiangsu-carephar-pharmaceutical-describes-new-at2-receptor-agonists</link>
    </item>
    <item>
      <title>Shanghai Meiyue Biotech Development presents new molecular glue degraders</title>
      <description>
        <![CDATA[Shanghai Meiyue Biotech Development Co. Ltd. has divulged molecular glue degraders comprising an E3 ubiquitin-protein ligase/proto-oncogene Vav (VAV1) interaction inducer and VAV1 degradation inducer. They are designed for potential use in the treatment of cancer, autoimmune diseases, cardiovascular, renal, metabolic, inflammatory and neurological disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730658</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730658-shanghai-meiyue-biotech-development-presents-new-molecular-glue-degraders</link>
    </item>
    <item>
      <title>Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists</title>
      <description>
        <![CDATA[Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the treatment of depression, bipolar disorder, substance abuse and dependence, eating disorders, schizophrenia, cognitive disorders, Parkinson’s disease and Huntington's disease, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730657</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730657-sichuan-kelun-pharmaceutical-research-institute-discovers-gpr6-inverse-agonists</link>
    </item>
    <item>
      <title>Suzhou Spring-Sea Bio-Pharmaceuticals discloses new GLP-1R/GCGR/GIPR agonists</title>
      <description>
        <![CDATA[Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. has synthesized glucagon-like peptide 1 receptor (GLP-1R), glucagon receptor (GCGR) and gastric inhibitory polypeptide receptor (GIPR) agonists that are potentially useful for the treatment of dyslipidemia, hepatic steatosis, metabolic syndrome, obesity and type 2 diabetes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730656</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730656-suzhou-spring-sea-bio-pharmaceuticals-discloses-new-glp-1r-gcgr-gipr-agonists</link>
    </item>
    <item>
      <title>Chinese researchers identify new antibody-drug conjugates</title>
      <description>
        <![CDATA[Scientists from Jiangsu Hengrui Pharmaceuticals Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. have disclosed antibody-drug conjugates comprising antibodies covalently linked camptothecin derivatives through a linker reported to be useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730655</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730655-chinese-researchers-identify-new-antibody-drug-conjugates</link>
    </item>
    <item>
      <title>BGB-58067 exerts relevant antitumor activity in MTAP-deficient tumors</title>
      <description>
        <![CDATA[Homozygous deletion of methylthioadenosine phosphorylase (MTAP), present in ~15% of tumors, leads to accumulation of methylthioadenosine and partial inhibition of protein arginine methyltransferase 5 (PRMT5), creating a synthetic-lethal vulnerability that sensitizes tumors to PRMT5-targeted therapies. Researchers from Beone Medicines Ltd. presented preclinical efficacy data of BGB-58067, an MTA-cooperative PRMT5 inhibitor, in models of tumors with MTAP-deficiency.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730641</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730641-bgb-58067-exerts-relevant-antitumor-activity-in-mtap-deficient-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Dividing-cancer-cell-target.webp?t=1764171254" type="image/jpeg" medium="image" fileSize="760640">
        <media:title type="plain">Dividing cancer cells in the cross hairs</media:title>
      </media:content>
    </item>
    <item>
      <title>Pfizer presents auristatin S ADC for GPNMB tumors</title>
      <description>
        <![CDATA[An advantage of antibody-drug conjugates (ADCs) is that they allow targeted delivery of cytotoxic agents into tumors, thus improving the therapeutic index. Pfizer Inc. has developed a new ADC, PF-08046033, that contains auristatin S (AurS) as the cytotoxic payload and targets transmembrane glycoprotein NMB (GPNMB).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730638</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730638-pfizer-presents-auristatin-s-adc-for-gpnmb-tumors</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Antibody-drug-conjugate-illustration.webp?t=1643920520" type="image/png" medium="image" fileSize="124892">
        <media:title type="plain">Antibody-drug conjugate illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>KHN-702 as a potent nonopioid analgesic</title>
      <description>
        <![CDATA[Chengdu Kanghong Pharmaceutical Group Co. Ltd. is developing a nonopioid Nav1.8 inhibitor, KHN-702. The effects of KHN-702 were evaluated both in vitro and in vivo, in a plantar incision pain model, and results were presented at the recent American Academy of Neurology meeting in Chicago.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730637</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730637-khn-702-as-a-potent-nonopioid-analgesic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Pain-illustration.webp?t=1598381807" type="image/png" medium="image" fileSize="413040">
        <media:title type="plain">Pain illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>NEO-811 overcomes HIF resistance in renal cancer</title>
      <description>
        <![CDATA[Neomorph Inc.’s NEO-811 is a molecular glue degrader designed to induce targeted degradation of ARNT and suppress this signaling pathway implicated in clear cell renal cell carcinoma (ccRCC). Targeting ARNT offers a complementary strategy to broadly disrupt oncogenic HIF signaling in ccRCC.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730636</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730636-neo-811-overcomes-hif-resistance-in-renal-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Endocrine/Endocrine-Adrenal-Glands-Kidneys.webp?t=1745258325" type="image/jpeg" medium="image" fileSize="519266">
        <media:title type="plain">Illustration highlighting the adrenal glands and kidneys</media:title>
      </media:content>
    </item>
    <item>
      <title>Milestone in Atrium and BMS cardiovascular collaboration</title>
      <description>
        <![CDATA[Atrium Therapeutics Inc. has earned a $15 million development milestone payment from Bristol Myers Squibb Co. (BMS) for the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the companies’ ongoing collaboration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730635</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730635-milestone-in-atrium-and-bms-cardiovascular-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Vacsular-system.webp?t=1639599093" type="image/png" medium="image" fileSize="555720">
        <media:title type="plain">Vascular system</media:title>
      </media:content>
    </item>
    <item>
      <title>Seed funding at Ferrosa Therapeutics</title>
      <description>
        <![CDATA[Ferrosa Therapeutics AG has announced a $3.5 million seed financing to support the development of a first-in-class bispecific antibody (FRS-101) to treat anemia of inflammation across chronic kidney disease, autoimmune disease and oncology indications.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730634</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730634-seed-funding-at-ferrosa-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Seedling-coins.webp?t=1588792056" type="image/png" medium="image" fileSize="390216">
        <media:title type="plain">Coins and seedling</media:title>
      </media:content>
    </item>
    <item>
      <title>Detecting the invisible: minimal residual disease at AACR 2026</title>
      <description>
        <![CDATA[Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision. As increasingly sensitive technologies reveal traces of cancer that persist after therapy, MRD is emerging as both a biological challenge and a clinical opportunity, especially as new data illuminate its complexity across hematologic and solid tumors. This topic was addressed at the 2026 American Association for Cancer Research (AACR) annual meeting. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730633</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730633-detecting-the-invisible-minimal-residual-disease-at-aacr-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-tumor-tissue-growth.webp?t=1777041759" type="image/jpeg" medium="image" fileSize="653690">
        <media:title type="plain">Illustration of a tumor</media:title>
      </media:content>
    </item>
    <item>
      <title>Chengdu Mfs Pharma synthesizes new compounds for pain</title>
      <description>
        <![CDATA[Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for use as an anesthetic.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730598</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730598-chengdu-mfs-pharma-synthesizes-new-compounds-for-pain</link>
    </item>
    <item>
      <title>Fosun Pharma discovers new PKMYT1 inhibitors</title>
      <description>
        <![CDATA[Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. has patented Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730597</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730597-fosun-pharma-discovers-new-pkmyt1-inhibitors</link>
    </item>
    <item>
      <title>Mabwell discloses new ADAM9-targeting ADCs</title>
      <description>
        <![CDATA[Mabwell (Shanghai) Bioscience Co. Ltd. has synthesized antibody-drug conjugates comprising antibody or antigen-binding fragment targeting disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) covalently linked to a cytotoxic drug. They are described as potentially useful for the diagnosis and/or treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730596</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730596-mabwell-discloses-new-adam9-targeting-adcs</link>
    </item>
    <item>
      <title>Avacta Life Sciences patents FAP-activated camptothecin conjugates</title>
      <description>
        <![CDATA[Avacta Life Sciences Ltd. has disclosed drug conjugates consisting of a fibroblast activation protein-α (FAPα) cleavable moiety bonded to camptothecin derivatives through a linker that are potentially useful for the treatment of cancer, inflammation and fibrosis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730595</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730595-avacta-life-sciences-patents-fap-activated-camptothecin-conjugates</link>
    </item>
    <item>
      <title>Hetero Labs divulges new tyrosine kinase inhibitors</title>
      <description>
        <![CDATA[Hetero Labs Ltd. has reported tyrosine kinase inhibitors that are potentially useful for the treatment of cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730594</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730594-hetero-labs-divulges-new-tyrosine-kinase-inhibitors</link>
    </item>
    <item>
      <title>MICA/B GAALIE-mutant Ab shows preclinical efficacy in cancer models</title>
      <description>
        <![CDATA[The major histocompatibility complex class I polypeptide-related sequences A and B (MICA/B) are frequently expressed by cancer cells. In a recently published study, researchers from Icahn School of Medicine at Mount Sinai hypothesized that the therapeutic efficacy of anti-MICA/B antibodies could be enhanced through Fc optimization with three point mutations in the Fc region: G236A, A330L and I332E (GAALIE).]]>
      </description>
      <guid>http://www.bioworld.com/articles/730588</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730588-mica-b-gaalie-mutant-ab-shows-preclinical-efficacy-in-cancer-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Immuno-oncology-cancer-antibodies.webp?t=1776955680" type="image/jpeg" medium="image" fileSize="712239">
        <media:title type="plain">Antibodies surrounding cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>Mosperafenib, a paradox-breaking BRAF inhibitor in CRC</title>
      <description>
        <![CDATA[Researchers from F. Hoffmann-La Roche Ltd. and collaborators reported the preclinical efficacy profile of mosperafenib (RO-7276389), a next-generation BRAF inhibitor designed as an MAPK paradox breaker. The compound selectively inhibits oncogenic RAF signaling while avoiding RAF dimer-driven ERK activation, thereby overcoming a key mechanistic limitation of first-generation BRAF inhibitors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730587</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730587-mosperafenib-a-paradox-breaking-braf-inhibitor-in-crc</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Colorectal-cancer-3D-illustration.webp?t=1704985372" type="image/jpeg" medium="image" fileSize="302450">
        <media:title type="plain">Colorectal cancer 3D illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>INCA-036873 appears to be potent in CD70-expressing cancer</title>
      <description>
        <![CDATA[Incyte Corp. has developed and presented data for their CD70xCD3 bispecific antibody INCA-036873, which was designed to activate T cells and kill tumoral cells expressing CD70.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730586</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730586-inca-036873-appears-to-be-potent-in-cd70-expressing-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/3D-bispecific-antibodies.webp?t=1732120101" type="image/jpeg" medium="image" fileSize="146730">
        <media:title type="plain">3d rendering of bispecific antibodies</media:title>
      </media:content>
    </item>
    <item>
      <title>Synendos’ first-in-class SERI effective in models of anxiety</title>
      <description>
        <![CDATA[At the recently concluded meeting of the American Academy of Neurology, Synendos Therapeutics AG reported preclinical data from the pharmacological characterization of SYT-510, which is the first selective endocannabinoid reuptake inhibitor (SERI) to enter the clinic for the potential treatment of disorders affecting the CNS, such as anxiety or movement disorders. A new class of endocannabinoid system (ECS) modulators, SERIs potently and selectively inhibit endocannabinoid reuptake to help the ECS restore normal brain function under disease conditions.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730585</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730585-synendos-first-in-class-seri-effective-in-models-of-anxiety</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Silhouette-of-head-and-brainwith-fractal-art.webp?t=1776955680" type="image/jpeg" medium="image" fileSize="995438">
        <media:title type="plain">Silhouette of head and brainwith fractal art</media:title>
      </media:content>
    </item>
    <item>
      <title>Next-gen ADC targeting CD37 shows antileukemic activity in AML, MDS models</title>
      <description>
        <![CDATA[More effective treatments are needed for patients with myelodysplastic syndrome (MDS), a heterogeneous group of myeloid disorders that frequently progress to acute myeloid leukemia (AML). In a recent publication, Debiopharm SA and The Ohio State University demonstrate that MDS cells express CD37 and that both AML and MDS cells exhibit efficient internalization of this receptor. Debio-1562M, under development at Debiopharm, is a next-generation antibody-drug conjugate (ADC) targeting CD37.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730584</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730584-next-gen-adc-targeting-cd37-shows-antileukemic-activity-in-aml-mds-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-AML-acute-myeloid-leukemia-myeloblasts.webp?t=1760622065" type="image/jpeg" medium="image" fileSize="197137">
        <media:title type="plain">Photomicrograph of bone marrow aspirate showing myeloblasts of acute myeloid leukemia</media:title>
        <media:description type="plain">Acute myeloid leukemia.</media:description>
      </media:content>
    </item>
    <item>
      <title>AZD-4956 enhances efficacy and delays resistance in combination therapies</title>
      <description>
        <![CDATA[DNA polymerase θ (POLθ) plays a central role in microhomology-mediated end joining (MMEJ), an error-prone DSB repair pathway. Under normal conditions, MMEJ acts as a backup repair mechanism. However, in HRR-deficient tumors, reliance on POLlθ-driven MMEJ is markedly increased, making POLθ essential for cancer cell survival. Researchers from Astrazeneca plc reported the discovery and characterization of AZD-4956, a POLθ inhibitor that can be used in combination with PARP inhibitors and other DNA-damaging agents.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730583</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730583-azd-4956-enhances-efficacy-and-delays-resistance-in-combination-therapies</link>
    </item>
    <item>
      <title>AACR 2026: The age of agentic AI in oncology</title>
      <description>
        <![CDATA[New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of experimental compounds fail in clinical trials, underscoring the need for strategies that better capture human biology. Many of these techniques were showcased at the 2026 American Association for Cancer Research (AACR) annual meeting.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730582</guid>
      <pubDate>Thu, 23 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730582-aacr-2026-the-age-of-agentic-ai-in-oncology</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/Abstract-digital-human-face-AI.webp?t=1776955679" type="image/jpeg" medium="image" fileSize="303061">
        <media:title type="plain">Illustration of human face that looks abstract and digital</media:title>
      </media:content>
    </item>
    <item>
      <title>AI opens the way to systematic risk assessment of zoonotic potential of viruses</title>
      <description>
        <![CDATA[Researchers in the U.K. have developed an AI-driven method of identifying viruses in wild animals with the potential to spillover into humans. The technique makes it possible to use the genome sequences of the spike proteins by which viruses enter host cells to assess the potential to infect humans without having to isolate an individual virus and tests its infectivity in the lab.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730553</guid>
      <pubDate>Wed, 22 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730553-ai-opens-the-way-to-systematic-risk-assessment-of-zoonotic-potential-of-viruses</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Zoonosis-heart-nosed-bats-hanging.webp?t=1776870425" type="image/jpeg" medium="image" fileSize="707396">
        <media:title type="plain">Heart-nosed bats (Cardioderma cor) hanging from the rafters</media:title>
      </media:content>
    </item>
    <item>
      <title>Ruijin Hospital and Shanghai Jiao Tong University discover GSPT1 degradation inducers</title>
      <description>
        <![CDATA[Researchers from Ruijin Hospital and Shanghai Jiao Tong University have patented molecular glue degraders, specifically eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers that are potentially useful for the treatment of cancer, autoimmune disease and inflammatory disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730570</guid>
      <pubDate>Wed, 22 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730570-ruijin-hospital-and-shanghai-jiao-tong-university-discover-gspt1-degradation-inducers</link>
    </item>
    <item>
      <title>Jiangsu Vcare Pharmatech identifies new IL-17A inhibitors</title>
      <description>
        <![CDATA[Jiangsu Vcare Pharmatech Co. Ltd. has described interleukin-17A (IL-17A) inhibitors reported to be useful for the treatment of psoriasis, psoriatic arthritis and spondyloarthritis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730569</guid>
      <pubDate>Wed, 22 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730569-jiangsu-vcare-pharmatech-identifies-new-il-17a-inhibitors</link>
    </item>
    <item>
      <title>Singularity Pharma discloses new mitragynine analogues</title>
      <description>
        <![CDATA[Singularity Pharma Ltd. has divulged mitragynine analogues that are potentially useful for the treatment of postoperative pain, depression, opioid dependence, opioid withdrawal, inflammatory and psychiatric disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730568</guid>
      <pubDate>Wed, 22 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730568-singularity-pharma-discloses-new-mitragynine-analogues</link>
    </item>
    <item>
      <title>Hinova Pharmaceuticals presents new prodrugs of orforglipron</title>
      <description>
        <![CDATA[Hinova Pharmaceuticals Inc. has synthesized prodrugs of orforglipron (a glucagon-like peptide 1 receptor [GLP-1R] agonist) for the potential treatment of diabetes, obesity, hypertension, arteriosclerosis, cerebral infarction, arthritis, polycystic ovary syndrome and Parkinson’s disease, among others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730567</guid>
      <pubDate>Wed, 22 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730567-hinova-pharmaceuticals-presents-new-prodrugs-of-orforglipron</link>
    </item>
  </channel>
</rss>
